GlassScriptIstent Infinite Trabecular Micro-Bypass System Model Is3
Payments companies reported to CMS as associated with Istent Infinite Trabecular Micro-Bypass System Model Is3. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Istent Infinite Trabecular Micro-Bypass System Model Is3, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Istent Infinite Trabecular Micro-Bypass System Model Is3
These are the largest totals companies reported as associated with Istent Infinite Trabecular Micro-Bypass System Model Is3. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Iqbal Ahmed | Salt Lake City, UT | Ophthalmology | $35,437.50 |
| Jason Bacharach | Petaluma, CA | Glaucoma Specialist | $14,000.00 |
| Sahar Bedrood | Pasadena, CA | Retina Specialist | $11,121.80 |
| Inder Singh | Racine, WI | Ophthalmology | $8,717.14 |
| Mark Gallardo | Las Cruces, NM | Ophthalmology | $5,604.95 |
| Nathan Radcliffe | New York, NY | Ophthalmology | $3,750.00 |
| Oluwatosin Smith | Dallas, TX | Ophthalmology | $2,550.00 |
| Albert Khouri | Newark, NJ | Ophthalmology | $2,400.00 |
| Scott Walsman | Jersey City, NJ | Ophthalmology | $2,307.46 |
| Eric Donnenfeld | Garden City, NY | Ophthalmology | $2,200.00 |
Prescribed Istent Infinite Trabecular Micro-Bypass System Model Is3?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.